[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495822":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":57,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"University of Illinois at Chicago","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine",null,"Dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation",[13],"Drug: Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":10},"Placebo","Normal Saline, midazolam, and fentanyl (titrated to effect) to facilitate the intubation",[18],{"type":19,"name":9,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation",[9],[23],"Precedex",[25],{"name":26,"affiliation":27,"role":28},"David Glick, MD","Department of Anesthesiology Head","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Alexandra Barabanova, MS","CONTACT","(312)355-5733","barabano@uic.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University of Illinois","RECRUITING","Chicago","Illinois","60612","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-87.65005,41.85003,{"lat":48,"lon":47},[51],{"name":31,"role":32,"phone":52,"phoneExt":10,"email":10},"312-355-5733",{"type":28,"investigatorFullName":54,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"David Glick","100495822","comparison-of-two-sedation-regimens-for-awake-fiberoptic-intubation-100495822",false,"NCT05736198","Comparison of Two Sedation Regimens for Awake Fiberoptic Intubation","Inclusion Criteria:\n\n* Subjects with potentially difficult airways who require awake fiberoptic intubations will be identified from the OR schedule and the pre-operative clinic workups.\n\nExclusion Criteria:\n\n* Anyone who does not meet the inclusion criteria","ALL","18 Years",{"count":64,"type":65},96,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to examine the effects of different sedation drugs used for the awake fiberoptic intubation procedure. Benzodiazapines and narcotics (such as midazolam and fentanyl) are standard drugs used for sedation during awake fiberoptic intubation. Dexmedetomidine, midazolam, and fentanyl are approved by the Food and Drug Administration (FDA) procedural sedation. These drugs might be given to the patient regardless of their participation in the study.\n\nIn addition to midazolam and fentanyl study subjects will also receive either dexmedetomidine or a placebo (a salt solution that contains no drug). It is believed that dexmedetomidine will not slow down breathing as much as the combination of the valium-like drug and narcotic. In our study, we are trying to determine if this is the best drug for sedation during an awake fiberoptic procedure.",[69,70],"Awake Fiberoptic Intubation","Difficult Airway",[9],"2024-11-26",{"date":74,"type":75},"2024-11-29","ACTUAL",{"date":77,"type":75},"2024-08-12",{"date":79,"type":65},"2034-03-01",{"name":5,"class":6},1]